ASAcza Kalica Buarque da Silva

Acza Kalica Buarque da Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Acza Kalica Buarque da Silva has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis

    by Marcela da Silva Kazitani Cunha, Hilária Saugo Faria, Lucas Mendes Barbosa, Leonardo Reischoffer Do Nascimento, Carlos Henrique de Oliveira Ferreira, Karlos Daniell Araújo dos Santos, Lucas Cael Azevedo Ramos Bendaham, Acza Kalica Buarque da Silva, Altair Pereira de Melo Neto, Wellgner Fernandes Oliveira Amador, et al.

    Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.

  • Open Access

    Eficácia da D-manose como profilaxia da infecção recorrente do trato urinário: uma revisão sistemática e metanálise de ensaios clínicos randomizados controlados

    by Carlos Eduardo Franca Vargas, Antonio Mutarelli, Luis Gustavo Menegardo, Acza Kalica Buarque da Silva, Patricia Rocha Barros Vieira, Jiandra da Luz, Nicole Felix, Luis Claudio Santos Pinto

    Resumo Introdução: As infecções do trato urinário (ITUs) recorrentes afetam significativamente a qualidade de vida devido aos sintomas, aos efeitos sobre a atividade sexual, à dor persistente e ao uso recorrente de antibióticos. Esta revisão sistemática e metanálise teve como objetivo avaliar a eficácia da D-manose na prevenção de ITUs recorrentes. Métodos: Em maio de 2024, realizamos uma busca sistemática nas bases de dados PubMed, EMBASE e Cochrane Library por ensaios clínicos randomizados (ECRs) que comparassem o tratamento com D-manose à ausência de intervenção ou à terapia antibiótica padrão em pacientes com alto risco de ITU recorrente. Aplicamos um modelo de efeitos aleatórios para agrupar os riscos relativos (RR) e os intervalos de confiança (IC) de 95%. Resultados: Incluímos 6 ECRs envolvendo 1.167 participantes, dos quais 534 receberam D-manose e 521 (97,6%) eram mulheres. A D-manose não se associou a uma redução na ITU recorrente em comparação ao grupo controle (RR: 0,57; IC 95% 0,29 – 1,15; p < 0,01) ou ao uso de antibióticos (RR: 0,39; IC 95% 0,12 – 1,25; p < 0,01). Análises adicionais demonstraram que a D-manose não melhorou os desfechos em um subgrupo de mulheres na pós-menopausa. Conclusão: Nesta metanálise de ECRs, a D-manose não reduziu a incidência de ITUs recorrentes em comparação ao grupo controle ou ao tratamento com antibióticos em pacientes de alto risco.

  • Open Access

    Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials

    by Carlos Eduardo Franca Vargas, Antonio Mutarelli, Luis Gustavo Menegardo, Acza Kalica Buarque da Silva, Patricia Rocha Barros Vieira, Jiandra da Luz, Nicole Felix, Luis Claudio Santos Pinto

    Introduction: Recurrent urinary tract infections (UTIs) significantly impact the quality of life due to symptoms, effects on sexual activity, persistent pain, and recurrent antibiotic use. This systematic review and meta-analysis aimed to evaluate the efficacy of D-mannose in preventing recurrent UTIs.


  • Open Access

    Comparative Study Between Central Venoarterial ECMO and Peripheral Venoarterial ECMO in Patients With Post-Cardiotomy Cardiogenic Shock

    by José Edson Cristovão de Carvalho Júnior, Maryllia Vitória Pereira de Melo Cristóvão, Ana Lígia Pereira Maranhão, Brenda Bess Nascimento Arruda, Ana Carolina Araújo Pinho, Rafael Gonzaga Cerretti, Isabella de Noronha Rodrigues, Yasmin Martins Rosa, Priscila Silva Rosalino da Conceição, Acza Kalica Buarque da Silva, et al.

    Objective: This study aims to compare central and peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) approaches in patients with postcardiotomy cardiogenic shock, evaluating outcomes such as in-hospital mortality, vascular complications, and weaning success rates. Theoretical Framework: Postcardiotomy cardiogenic shock is a critical condition associated with high mortality rates, requiring advanced temporary circulatory support. Central VA-ECMO, characterized by direct cannulation of the aorta and right atrium, provides greater hemodynamic stability and physiological support but is associated with higher risks of hemorrhagic and infectious complications. Peripheral ECMO, implanted through femoral access, allows for faster and less complex deployment but is linked to vascular complications, such as limb ischemia and differential hypoxemia. The choice between techniques depends on clinical factors such as hemodynamic status, comorbidities, and the need for emergent or prolonged support. Method: A systematic review was conducted with a temporal scope from 2014 to 2024, including 14 studies identified in the PubMed, Scopus, and Web of Science databases. Inclusion criteria covered studies comparing central and peripheral VA-ECMO in adult patients with postcardiotomy cardiogenic shock, analyzing outcomes such as in-hospital mortality, vascular complications, and weaning success rates. Results and Discussion: Findings indicate that central ECMO is associated with greater hemodynamic stability and higher weaning success rates but presents higher risks of hemorrhagic complications and reoperations. In contrast, peripheral ECMO, more commonly used in emergencies, demonstrated faster deployment and lower bleeding rates but a higher incidence of vascular complications such as limb ischemia. Hybrid strategies and the use of additional devices, such as intra-aortic balloon pumps and Impella, showed potential to optimize outcomes but are associated with high costs and increased complication rates. Research Implications: This study highlights the need for multicenter and long-term clinical trials to refine selection criteria between central and peripheral ECMO, as well as to explore hybrid strategies to improve outcomes. Future research should also evaluate the impact of these techniques on quality of life and cost-effectiveness. Originality/Value: This systematic review provides a comprehensive analysis of the differences between central and peripheral ECMO in patients with postcardiotomy cardiogenic shock, contributing to informed clinical decision-making and the improvement of management protocols.

  • Open Access

    ANÁLISE TÉCNICA DA EFICÁCIA TERAPÊUTICA DA INTRADERMOTERAPIA NO TRATAMENTO DA GORDURA LOCALIZADA

    by Marcos Daniel Seabra Santos, Nayanne Leal Do Monte, Mariah Eduarda Amaral Mateus Vasconcelos, Luiz Henrique de Lima Davino, Lucas Gregório Torres, Paloma Raissa da Silva Madeira, Lucas Prazeres Pereira, Leonardo de Andrade Vitorio, Laiza Maria da Silva Queiroz, Jeanne Ferreira Vilela Generoso, et al.

    A necessidade de um padrão de beleza humano tornou-se um fenômeno comum na sociedade, fazendo com que houvesse a busca por um corpo ideal e sua reavaliação. A gordura local é definida como um distúrbio celular do metabolismo das células de gordura ou seu crescimento anormal, comum nas principais partes do corpo, como: coxas, abdômen e coxas. A Intradermoterapia é um procedimento que usa injeções intradérmicas de agentes lipolíticos altamente diluídos em uma área de gordura localizada. Ademais, este trabalho possui o objetivo de a eficácia da terapia intradérmica (Intradermoterapia) no tratamento gordura localizada. Para isso, a metodologia aplicada é qualitativa e bibliográfica, sendo que revisão literária ocorreu por meio de base de dados do google acadêmico, PubMed, Scielo e demais informações eletrônicas de respaldo no território nacional.

  • Open Access

    ANÁLISE TÉCNICA DA EFICÁCIA TERAPÊUTICA DA INTRADERMOTERAPIA NO TRATAMENTO DA GORDURA LOCALIZADA

    by Marcos Daniel Seabra Santos, Nayanne Leal Do Monte, Mariah Eduarda Amaral Mateus Vasconcelos, Luiz Henrique de Lima Davino, Lucas Gregório Torres, Paloma Raissa da Silva Madeira, Lucas Prazeres Pereira, Leonardo de Andrade Vitorio, Laiza Maria da Silva Queiroz, Jeanne Ferreira Vilela Generoso, et al.

    A necessidade de um padrão de beleza humano tornou-se um fenômeno comum na sociedade, fazendo com que houvesse a busca por um corpo ideal e sua reavaliação. A gordura local é definida como um distúrbio celular do metabolismo das células de gordura ou seu crescimento anormal, comum nas principais partes do corpo, como: coxas, abdômen e coxas. A Intradermoterapia é um procedimento que usa injeções intradérmicas de agentes lipolíticos altamente diluídos em uma área de gordura localizada. Ademais, este trabalho possui o objetivo de a eficácia da terapia intradérmica (Intradermoterapia) no tratamento gordura localizada. Para isso, a metodologia aplicada é qualitativa e bibliográfica, sendo que revisão literária ocorreu por meio de base de dados do google acadêmico, PubMed, Scielo e demais informações eletrônicas de respaldo no território nacional.

  • Open Access

    EFFECT OF FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE ON HEMATIMETRIC INDICES AND IRON PROFILE IN CHRONIC HEMODIALYSIS PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

    by Acza Kalica Buarque da Silva¹, Luis Claudio Santos Pinto², Patrícia Rocha Barros Vieira³, Lucas Mendes Barbosa⁴, Jiandra da Luz⁵, Luís Gustavo Menegardo Siqueira de Oliveira⁶, Antonio Mutarelli⁴

    Introduction: Intravenous iron therapy plays a fundamental role in the treatment of anemia in patients with chronic kidney disease (CKD) undergoing hemodialysis, improving survival rates and quality of life. Ferric carboxymaltose (FCM) is an alternative iron compound that allows for larger single doses, resulting in less frequent administration compared to iron sucrose. Although the choice of formulation and frequency of administration vary among centers, FCM presents an effective option for patients on hemodialysis. With its stability and controlled release of iron, FCM is a valuable option for these patients. Methods: We conducted a systematic search in PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) comparing the effect of Iron Sucrose versus Ferric Carboxymaltose in patients undergoing Chronic Hemodialysis and reporting outcomes including (1) hemoglobin (Hb), (2) ferritin, (3) adverse effects, (4) hospitalizations, and (5) mortality. Data were extracted from reports published up to May 30, 2024, and quality assessment was performed following Cochrane recommendations. We pooled mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI), using a random-effects model (IV, Random, 95% CI) to accommodate variability among studies. We used R version 4.3.2 for all statistical analyses. Results: Our meta-analysis included 3 RCTs, comprising 270 patients, of whom 137 were randomized to the FCM group. Compared with the control group, FCM significantly reduced ferritin levels (MD -52.95; 95% CI: -89.43 to -16.46; p< 0.05). However, there were no significant differences in hemoglobin levels (MD -0.19; 95% CI: -0.57 to 0.18; p=0.31) between groups. This lack of significant difference suggests that treatment with FCM does not negatively affect hemoglobin levels compared to the control. Furthermore, regarding adverse effects, our meta-analysis evaluated three main categories: infection (RR 0.80; 95% CI: 0.55 to 1.14; p=0.21), local reaction (RR 0.88; 95% CI: 0.13 to 5.72; p=0.89), and drug intolerance (RR 0.98; 95% CI: 0.10 to 10.00; p=0.99). Additionally, we assessed mortality (RR 0.32; 95% CI: 0.09 to 1.15; p=0.081). Conclusion: Our meta-analysis suggests a difference in ferritin concentration between the FCM (Ferric Carboxymaltose) group and the control (Iron Sucrose) group, with the control group having higher levels than the intervention group.